EA201992825A1 - THREE COMPONENT COMBINED ANTIBODIES - Google Patents
THREE COMPONENT COMBINED ANTIBODIESInfo
- Publication number
- EA201992825A1 EA201992825A1 EA201992825A EA201992825A EA201992825A1 EA 201992825 A1 EA201992825 A1 EA 201992825A1 EA 201992825 A EA201992825 A EA 201992825A EA 201992825 A EA201992825 A EA 201992825A EA 201992825 A1 EA201992825 A1 EA 201992825A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibodies
- component combined
- combined antibodies
- component
- control point
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Данное изобретение относится к трехкомпонентной комбинированной терапии с применением антител анти-TIGIT, антител анти-PVRIG и ингибиторов контрольных точек, включая антитела анти-PD-1 или анти-PD-L1.This invention relates to three-part combination therapy using anti-TIGIT antibodies, anti-PVRIG antibodies and control point inhibitors, including anti-PD-1 or anti-PD-L1 antibodies.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862618005P | 2018-01-16 | 2018-01-16 | |
PCT/IB2018/000696 WO2018220446A1 (en) | 2017-06-01 | 2018-06-01 | Triple combination antibody therapies |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201992825A1 true EA201992825A1 (en) | 2020-04-15 |
Family
ID=70546484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201992825A EA201992825A1 (en) | 2018-01-16 | 2018-06-01 | THREE COMPONENT COMBINED ANTIBODIES |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA201992825A1 (en) |
-
2018
- 2018-06-01 EA EA201992825A patent/EA201992825A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019014265A (en) | Triple combination antibody therapies. | |
TR201901445T4 (en) | Il2rbeta / common gamma chain antibodies. | |
PH12019500923A1 (en) | Anti-pd-1 antibodies and compositions | |
EA202091130A1 (en) | LYOPHILIZED PREPARATION OF MONOCLONAL ANTIBODY TO TRANSTYRETIN | |
EA201891028A1 (en) | TRISPECIFIC AND / OR TRIVALENT BINDING PROTEINS FOR PREVENTION OR TREATMENT OF INFECTION CAUSED BY HIV | |
MX2016015263A (en) | Human antibodies to middle east respiratory syndrome -coronavirus spike protein. | |
EA202092000A1 (en) | EGFR DIMERIZATION INHIBITORS AND THEIR USE | |
EA202190609A1 (en) | ANTIBODIES AGAINST HLA-G, COMPOSITIONS CONTAINING ANTIBODIES AGAINST HLA-G, AND METHODS OF APPLICATION ANTIBODIES AGAINST HLA-G | |
BR112016027881A2 (en) | pdl-1 and pd-1 antagonists for the treatment of hpv-negative cancers | |
PH12019500145A1 (en) | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-á) | |
EA201990672A1 (en) | ANTIBODIES SPECIFICALLY RELATING TO PD-1, AND THEIR FUNCTIONAL FRAGMENTS | |
EA201890578A1 (en) | PREVENTION, TREATMENT AND REDUCTION (PERSISTENT) OF POST-TRAUMATIC HEADACHE | |
PH12021550361A1 (en) | Anti-avb8 antibodies and compositions and uses thereof | |
EA201991729A1 (en) | ANTIBODIES TO TGF-BETA AND THEIR APPLICATION | |
BR112021012631A2 (en) | Anti-ctla4 antibodies and methods of using them | |
MX2019010797A (en) | Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer. | |
EA202190138A1 (en) | ANTI-SIRP-BETA1 ANTIBODIES AND METHODS OF THEIR USE | |
EA201792561A1 (en) | ANTIBODIES AIMED ON MORPHOGENETIC BONE 9 PROTECTION (BMP9) AND METHODS OF THEIR APPLICATION | |
EA201991876A1 (en) | ANTIBODIES AGAINST FACTOR D AND THEIR APPLICATION | |
NZ729395A (en) | Therapeutic agent for cancer which comprises combination of il-18 and molecule-targeting antibody | |
EA201992318A1 (en) | COMPOSITIONS AND METHODS FOR DIAGNOSTIC AND TREATMENT OF PROSTATE CANCER USING A MOLECULE BINDING PROGASTRIN | |
EA201892368A1 (en) | ERBB INHIBITORS AND THEIR APPLICATION | |
AU2016348418A8 (en) | Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same | |
EA201791691A1 (en) | SINGLE-DOMAIN ANTIBODIES DIRECTED TO CD1d | |
EA201992315A1 (en) | COMPOSITIONS AND METHODS FOR TREATING LUNG CANCER |